Losing CD45 and various B-cell markers in a case of MYC-driven pediatric high-grade B-cell lymphoma, not otherwise specified that transformed from Burkitt’s lymphoma during rituximab-containing treatments: a case report-Reference-Cited by-同舟云学术

Losing CD45 and various B-cell markers in a case of MYC-driven pediatric high-grade B-cell lymphoma, not otherwise specified that transformed from Burkitt’s lymphoma during rituximab-containing treatments: a case report

Published:2022-11-16 Issue: Volume: Page:
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Xue Xuemin,Fu Libing,Qiu Tian,Cao Zheng,Wang Xiaojun,Rao Wei,Luo Yiyang,He Lejian,Feng Xiaoli^ORCID

Funder

Beijing Hope Run Special Fund of Cancer Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00428-022-03433-1.pdf

Reference11 articles.

1. Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res: Off J Am Assoc Cancer Res 14:1561–1570. https://doi.org/10.1158/1078-0432.CCR-07-1254

2. Nakamaki T, Fukuchi K, Nakashima H, Ariizumi H, Maeda T, Saito B, Yanagisawa K, Tomoyasu S, Homma M, Shiozawa E, Yamochi-Onizuka T, Ota H (2012) CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma. Eur J Haematol 89:350–355. https://doi.org/10.1111/j.1600-0609.2012.01838.x

3. Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM (2005) The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol 32:616–621. https://doi.org/10.1111/j.0303-6987.2005.00305.x

4. Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K (2009) Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin’s lymphoma. Clin Cancer Res: Off J Am Assoc Cancer Res 15:2523–2530. https://doi.org/10.1158/1078-0432.CCR-08-1403

5. Donner LR, Mott FE, Tafur I (2001) Cytokeratin-positive, CD45-negative primary centroblastic lymphoma of the adrenal gland: a potential for a diagnostic pitfall. Arch Pathol Lab Med 125:1104–1106. https://doi.org/10.5858/2001-125-1104-CPCNPC